Pfizer Inc. is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.
Tag Archive for: Medicines Patent Pool (MPP)
China is in talks with Pfizer Inc. to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm’s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.
India’s Hetero said on Tuesday that its generic version of Paxlovid, an antiviral treatment for COVID-19 developed by Pfizer Inc., was added to the World Health Organization’s prequalification list, which serves as a benchmark for procurement of medicines by developing countries.
